Valneva receives JE vaccine supply contract from US DoD
25 Sep 2023
VaccineDrug Approval
Preview
Source: Pharmaceutical Technology
Valneva will supply a minimum of $32m worth of IXIARO vaccines to the US DoD. Credit: MasterTux from Pixabay.
Valneva has received a contract from the US Department of Defense (DoD) for the delivery of its Japanese encephalitis (JE) vaccine, IXIARO.
The company will supply a minimum of $32m worth of IXIARO vaccines as part of the new one-year contract.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Dtcp Vaccine in Tetanus GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - DTwP-Hep B-IPV-Hib Vaccine in Poliomyelitis GlobalData
View allCompanies IntelligenceValneva SEDodView all
DoD can also purchase additional doses during the next 12 months. Deliveries of the vaccines will begin immediately.
IXIARO is the only JE vaccine that has received approval from the US Food and Drug Administration (FDA).
Valneva developed the vaccine through a research and development agreement with the Walter Reed Army Institute of Research.
The company is responsible for marketing and supplying this vaccine directly to the military and private travel market in the US.
Valneva chief commercial officer Dipal Patel stated: “We are excited to continue our long-term relationship with the DoD.
“The US military has trusted IXIARO for over ten years to help protect military personnel, their families, civilian government service personnel and government contractors from this potentially deadly disease.”
JE is an infectious disease endemic in South-East Asia, China and India. It has a fatality rate of around 30% in symptomatic patients and causes permanent brain damage in half of those who survive.
JE killed more than 1,200 children in one month during an epidemic outbreak in the Indian state of Uttar Pradesh and Nepal.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.